{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014815","form_type":"8-K","ticker":"CURX","cik":"0002025942","company_name":"Curanex Pharmaceuticals Inc","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.400097+00:00","generated_at":"2026-05-15T07:53:37.348462+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Curanex expands drug pipeline to include cancer cachexia, a multi-billion-dollar market","bullets":["Company adds cancer cachexia as a new core indication beyond its six existing programs (ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout).","Global cancer cachexia market was $2.54B in 2024, projected to reach $3.90B by 2033; no approved therapies in US.","Lead program Phyto-N remains in preclinical for ulcerative colitis; Company evaluating further development opportunities in cachexia.","Management sees this as key step in evolving into a broader therapeutics company."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014815","json":"https://secwatch.observer/filing/0001493152-26-014815.json","markdown":"https://secwatch.observer/filing/0001493152-26-014815.md","text":"https://secwatch.observer/filing/0001493152-26-014815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226014815/0001493152-26-014815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226014815/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:53:37.348462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}